Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Hormone Molecular Biology and Clinical Investigation

Editor-in-Chief: Chetrite, Gérard S.

Editorial Board: Alexis, Michael N. / Baniahmad, Aria / Beato, Miguel / Bouillon, Roger / Brodie, Angela / Carruba, Giuseppe / Chen, Shiuan / Cidlowski, John A. / Clarke, Robert / Coelingh Bennink, Herjan J.T. / Darbre, Philippa D. / Drouin, Jacques / Dufau, Maria L. / Edwards, Dean P. / Falany, Charles N. / Fernandez-Perez, Leandro / Ferroud, Clotilde / Feve, Bruno / Flores-Morales, Amilcar / Foster, Michelle T. / Garcia-Segura, Luis M. / Gastaldelli, Amalia / Gee, Julia M.W. / Genazzani, Andrea R. / Greene, Geoffrey L. / Groner, Bernd / Hampl, Richard / Hilakivi-Clarke, Leena / Hubalek, Michael / Iwase, Hirotaka / Jordan, V. Craig / Klocker, Helmut / Kloet, Ronald / Labrie, Fernand / Mendelson, Carole R. / Mück, Alfred O. / Nicola, Alejandro F. / O'Malley, Bert W. / Raynaud, Jean-Pierre / Ruan, Xiangyan / Russo, Jose / Saad, Farid / Sanchez, Edwin R. / Schally, Andrew V. / Schillaci, Roxana / Schindler, Adolf E. / Söderqvist, Gunnar / Speirs, Valerie / Stanczyk, Frank Z. / Starka, Luboslav / Sutter, Thomas R. / Tresguerres, Jesús A. / Wahli, Walter / Wildt, Ludwig / Yang, Kaiping / Yu, Qi

CiteScore 2018: 2.43

SCImago Journal Rank (SJR) 2018: 0.947
Source Normalized Impact per Paper (SNIP) 2018: 0.837

See all formats and pricing
More options …
Volume 30, Issue 3


Long-term dutasteride therapy in men with benign prostatic hyperplasia alters glucose and lipid profiles and increases severity of erectile dysfunction

Abdulmaged Traish
  • Corresponding author
  • Department of Biochemistry and Department of Urology, Boston University School of Medicine, 715 Albany Street; A502, Boston, MA 02478, USA
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Karim Sultan Haider / Gheorghe Doros
  • Department of Biostatistics and Epidemiology, Boston University School of Public Health, Boston, MA 02118, USA
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Ahmad Haider
Published Online: 2017-06-21 | DOI: https://doi.org/10.1515/hmbci-2017-0015



Dutasteride has been successfully used in treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). However, dutasteride inhibits 5α-reductase type 1 and type 2 enzymes and may compromises glucocorticoids and androgen metabolism and alters metabolic function resulting in undesirable metabolic and sexual adverse side effects.


The aim of this study was to investigate the long-term adverse effects of dutasteride therapy in men with BPH on: i) blood glucose, ii) glycated hemoglobin (HbA1c), iii) low density lipoprotein-cholesterol (LDL-C); high density lipoprotein-cholesterol (HDL-C) and total cholesterol (TC), iv) testosterone (T), v) liver alanine and aspartate aminotransferases (ALT and AST) and vi) erectile dysfunction (ED).


A retrospective registry study, with a cohort of 230 men aged between 47 and 68 years (mean 57.78 ± 4.81) were treated with dutasteride (0.5 mg/day) for LUTS, secondary to BPH. A second cohort of 230 men aged between 52 and 72 years (mean 62.62 ± 4.65) were treated with tamsulosin (0.4 mg). All men were followed up for 36–42 months. At intervals of 3–6 months, and at each visit, plasma glucose, HbA1c, TC, LDL-cholesterol, T levels and liver alanine amino transferase (ALT) and aspartate aminotransferase (AST) were determined. Further patient assessment was made by the International Index of Erectile Function (IIEF-EF) questionnaire, the Aging Male Symptom (AMS) and International Prostate Symptom Scores (IPSS).


Long-term treatment with dutasteride therapy is associated with significant improvements in LUTS, as assessed by reduction in prostate volume, IPSS and prostate specific antigen (PSA). Long-term dutasteride therapy, however, resulted in increased blood glucose, HbA1c, TC and LDL levels, ALT and AST activities, AMS Score and reduced T levels and worsened ED as assessed by the IIEF-EF scores. No worsening of ED, glucose, HbA1c, ALT, AST, AMS were observed in men treated with tamsulosin. Most importantly, long-term dutasteride therapy resulted in reduction in total T levels, contributing to a state of hypogonadism.


Our findings suggest that long-term dutasteride therapy produces worsening of ED, reduced T levels and increased glucose, HbA1c and alters lipid profiles, suggesting induced imbalance in metabolic function. We strongly recommend that physicians discuss with their patients these potential serious adverse effects of long-term dutasteride therapy prior to instituting this form of treatment.

Keywords: dutasteride; glucose; lipid profiles; sexual adverse effects; testosterone


  • 1.

    Roehrborn CG, Perez IO, Roos EP, Calomfirescu N, Brotherton B, Wang F, et al. Efficacy and safety of a fixed-dose combination of dutasteride and tamsulosin treatment (Duodart™) compared with watchful waiting with initiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the management of treatment-naïve men with moderately symptomatic benign prostatic hyperplasia: 2-Year CONDUCT study results. Br J Urol Int. 2015;116:450–9.Google Scholar

  • 2.

    Bechis SK, Otsetov AG, Ge R, Olumi AF. Personalized medicine for the management of benign prostatic hyperplasia. J Urol. 2014;192:16–23.CrossrefPubMedGoogle Scholar

  • 3.

    Gupta AK, Charrette A. The efficacy and safety of 5alpha-reductase inhibitors in androgenetic alopecia: a network meta-analysis and benefit-risk assessment of finasteride and dutasteride. J Dermatol Treat. 2014;25:156–61.CrossrefGoogle Scholar

  • 4.

    Mella JM, Perret MC, Manzotti M, Catalano HN, Guyatt G. Efficacy and safety of finasteride therapy for androgenetic alopecia: a systematic review. Arch Dermatol. 2010;146:1141–50.PubMedGoogle Scholar

  • 5.

    Erdemir F, Harbin A, Hellstrom WJ. 5-Alpha reductase inhibitors and erectile dysfunction: the connection. J Sex Med. 2008;5:2917–24.CrossrefPubMedGoogle Scholar

  • 6.

    Traish AM, Hassani J, Guay AT, Zitzmann M, Hansen ML. Adverse side effects of 5alpha-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients. J Sex Med. 2011;8:872–84.CrossrefGoogle Scholar

  • 7.

    Traish AM. 5alpha-reductases in human physiology: an unfolding story. Endocr Pract. 2012;18:965–75.CrossrefPubMedGoogle Scholar

  • 8.

    Traish AM, Mulgaonkar A, Giordano N. The dark side of 5α-reductase inhibitors’ therapy: sexual dysfunction, high Gleason grade prostate cancer and depression. Korean J Urol. 2014;55:367–79.PubMedCrossrefGoogle Scholar

  • 9.

    Traish AM, Guay AT, Zitzmann M. 5α-Reductase inhibitors alter steroid metabolism and may contribute to insulin resistance, diabetes, metabolic syndrome and vascular disease: a medical hypothesis. Horm Mol Biol Clin Investig. 2014;20:73–80.PubMedGoogle Scholar

  • 10.

    Traish AM, Haider KS, Doros G, Haider A. Finasteride, not tamsulosin, increases severity of erectile dysfunction and decreases testosterone levels in men with benign prostatic hyperplasia. Horm Mol Biol Clin Investig. 2015;23:85–96.PubMedGoogle Scholar

  • 11.

    Traish AM, Melcangi RC, Bortolato M, Garcia-Segura LM, Zitzmann M. Adverse effects of 5α-reductase inhibitors: What do we know, don’t know, and need to know?. Rev Endocr Metab Disord. 2015;16:177–98.PubMedCrossrefGoogle Scholar

  • 12.

    Irwig MS, Kolukula S. Persistent sexual side effects of finasteride for male pattern hair loss. J Sex Med. 2011;8:1747–53.PubMedCrossrefGoogle Scholar

  • 13.

    Irwig MS. Persistent sexual side effects of finasteride: could they be permanent?. J Sex Med. 2012;9:2927–32.PubMedCrossrefGoogle Scholar

  • 14.

    Irwig MS. Depressive symptoms and suicidal thoughts among former users of finasteride with persistent sexual side effects. J Clin Psychiatry. 2012;73:1220–3.CrossrefPubMedGoogle Scholar

  • 15.

    Irwig MS. Decreased alcohol consumption among former male users of finasteride with persistent sexual side effects: a preliminary report. Alcohol Clin Exp Res. 2013;37:1823–6.PubMedCrossrefGoogle Scholar

  • 16.

    Irwig MS. Androgen levels and semen parameters among former users of finasteride with persistent sexual adverse effects. JAMA Dermatol. 2014;150:1361–3.PubMedCrossrefGoogle Scholar

  • 17.

    Gur S, Kadowitz PJ, Hellstrom WJ. Effects of 5-alpha reductase inhibitors on erectile function, sexual desire and ejaculation. Expert Opin Drug Saf. 2013;12:81–90.CrossrefPubMedGoogle Scholar

  • 18.

    Ganzer CA, Jacobs AR, Iqbal F. Persistent sexual, emotional, and cognitive impairment post-finasteride: a survey of men reporting symptoms. Am J Mens Health. 2015;9:222–8.CrossrefPubMedGoogle Scholar

  • 19.

    Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G. ARIA3001 ARIA3002 and ARIA3003 study investigators. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology. 2002;60:434–41.CrossrefPubMedGoogle Scholar

  • 20.

    Upreti R, Hughes KA, Livingstone DE, Gray CD, Minns FC, Macfarlane DP, et al. 5α-Reductase type 1 modulates insulin sensitivity in men. J Clin Endocrinol Metab. 2014;99:E1397–406.PubMedCrossrefGoogle Scholar

  • 21.

    Joyce KE, Biggs ML, Djoussé L, Ix JH, Kizer JR, Siscovick DS, et al. Testosterone, dihydrotestosterone, sex hormone binding globulin and incident diabetes among older men: the cardiovascular health study. J Clin Endocrinol Metab. 2017;102:33–9.PubMedGoogle Scholar

  • 22.

    Livingstone DE, Barat P, Di Rollo EM, Rees GA, Weldin BA, Rog-Zielinska EA, et al. 5α-Reductase type 1 deficiency or inhibition predisposes to insulin resistance, hepatic steatosis, and liver fibrosis in rodents. Diabetes. 2015;64:447–58.PubMedCrossrefGoogle Scholar

  • 23.

    Kim S, Kwon H, Park JH, Cho B, Kim D, Oh SW, et al. A low level of serum total testosterone is independently associated with nonalcoholic fatty liver disease. BMC Gastroenterol. 2012;12:69.CrossrefPubMedGoogle Scholar

  • 24.

    Völzke H, Aumann N, Krebs A, Nauck M, Steveling A, Lerch MM, et al. Hepatic steatosis is associated with low serum testosterone and high serum DHEAS levels in men. Int J Androl. 2010;33:45–53.PubMedCrossrefGoogle Scholar

  • 25.

    Zhang H, Liu Y, Wang L, Li Z, Zhang H, Wu J, et al. Differential effects of estrogen/ androgen on the prevention of nonalcoholic fatty liver disease in the male rat. J Lipid Res. 2013;54:345–57.CrossrefPubMedGoogle Scholar

  • 26.

    Nasiri M, Nikolaou N, Parajes S, Krone NP, Valsamakis G, Mastorakos G, et al. 5α-Reductase type 2 regulates glucocorticoid action and metabolic phenotype in human hepatocytes. Endocrinology. 2015;156:2863–71.CrossrefPubMedGoogle Scholar

  • 27.

    Traish AM, Haider A, Doros G, Saad F. Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long-term registry study. Int J Clin Pract. 2014;68:314–29.CrossrefPubMedGoogle Scholar

  • 28.

    Saad F, Yassin A, Doros G, Haider A. Effects of long-term treatment with testosterone on weight and waist size in 411 hypogonadal men with obesity classes I-III: observational data from two registry studies. Int J Obes (Lond). 2016;40:162–70.CrossrefPubMedGoogle Scholar

  • 29.

    Haider A, Zitzmann M, Doros G, Isbarn H, Hammerer P, Yassin A. Incidence of prostate cancer in hypogonadal men receiving testosterone therapy: observations from 5-year median followup of 3 registries. J Urol. 2015;193:80–6.CrossrefPubMedGoogle Scholar

  • 30.

    Fwu CW, Eggers PW, Kaplan SA, Kirkali Z, Lee JY, Kusek JW. Long-term effects of doxazosin, finasteride and combination therapy on quality of life in men with benign prostatic hyperplasia. J Urol. 2013;190:187–93.PubMedCrossrefGoogle Scholar

  • 31.

    Fwu CW, Eggers PW, Kirkali Z, McVary KT, Burrows PK, Kusek JW. Change in sexual function in men with lower urinary tract symptoms (LUTS)/ benign prostatic hyperplasia (BPH) associated with long-term treatment with doxazosin, finasteride, and combined therapy. J Urol. 2014;191:1828–34.CrossrefGoogle Scholar

  • 32.

    Roehrborn CG, Siami P, Barkin J, Damiao R, Major-Walker K, Morrill B, et al. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol. 2008;179:616–21.PubMedCrossrefGoogle Scholar

  • 33.

    Andriole GL, Kirby R. Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia. Eur Urol. 2003;44:82–88.CrossrefPubMedGoogle Scholar

  • 34.

    Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010;362:1192–202.PubMedCrossrefGoogle Scholar

  • 35.

    Hazlehurst JM, Oprescu AI, Nikolaou N, Di Guida R, Grinbergs AE, Davies NP, et al. Dual-5α-reductase inhibition promotes hepatic lipid accumulation in man. J Clin Endocrinol Metab. 2016;101:103–13.CrossrefPubMedGoogle Scholar

  • 36.

    Dowman JK, Hopkins LJ, Reynolds GM, Armstrong MJ, Nasiri M, Nikolaou N, et al. Loss of 5α-reductase type 1 accelerates the development of hepatic steatosis but protects against hepatocellular carcinoma in male mice. Endocrinology. 2013;154:4536–47.PubMedCrossrefGoogle Scholar

  • 37.

    Livingstone DE, Di Rollo EM, Mak TC, Sooy K, Walker BR, Andrew R. Metabolic dysfunction in female mice with disruption of 5α-reductase 1. J Endocrinol. 2017;232:29–36.PubMedCrossrefGoogle Scholar

  • 38.

    Mohamedali HZ, Breunis H, Timilshina N, Alibhai SM. Changes in blood glucose and cholesterol levels due to androgen deprivation therapy in men with non-metastatic prostate cancer. Can Urol Assoc J. 2011;5:28–32.PubMedGoogle Scholar

  • 39.

    Oka R, Utsumi T, Endo T, Yano M, Kamijima S, Kamiya N, et al. Effect of androgen deprivation therapy on arterial stiffness and serum lipid profile changes in patients with prostate cancer: a prospective study of initial 6-month follow-up. Int J Clin Oncol. 2016;21:389–96.PubMedCrossrefGoogle Scholar

  • 40.

    Skeldon SC, Macdonald EM, Law MR, Huang A, Paterson JM, Mamdani MM, et al. The Cardiovascular safety of dutasteride. J Urol. 2017;197:1309-1314.PubMedGoogle Scholar

  • 41.

    Kaplan SA, Chung DE, Lee RK, Scofield S, Te AE. A 5-year retrospective analysis of 5alpha-reductase inhibitors in men with benign prostatic hyperplasia: finasteride has comparable urinary symptom efficacy and prostate volume reduction, but less sexual side effects and breast complications than dutasteride. Int J Clin Pract. 2012;66:1052–5.PubMedGoogle Scholar

  • 42.

    Park T, Choi JY. Efficacy and safety of dutasteride for the treatment of symptomatic benign prostatic hyperplasia (BPH): a systematic review and meta-analysis. World J Urol. 2014;32:1093–105.CrossrefPubMedGoogle Scholar

  • 43.

    Oztekin CV, Gur S, Abdulkadir NA, Lokman U, Akdemir AO, Cetinkaya M, et al. Incomplete recovery of erectile function in rat after discontinuation of dual 5-alpha reductase inhibitor therapy. J Sex Med. 2012;9:1773–81.CrossrefPubMedGoogle Scholar

  • 44.

    Pinsky MR, Gur S, Tracey AJ, Harbin A, Hellstrom WJ. The effects of chronic 5-alpha-reductase inhibitor (dutasteride) treatment on rat erectile function. J Sex Med. 2011;8:3066–74.PubMedCrossrefGoogle Scholar

  • 45.

    Wessells H, Roy J, Bannow J, Grayhack J, Matsumoto AM, Tenover L, et al. Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia. Urology. 2003;61:579–84.CrossrefPubMedGoogle Scholar

  • 46.

    Amory JK, Anawalt BD, Matsumoto AM, Page ST, Bremner WJ, Wang C, et al. The effect of 5a-reductase inhibition with dutasteride and finasteride on bone mineral density, serum lipoproteins, hemoglobin, prostate specific antigen and sexual function in healthy young men. J Urol. 2008;179:2333–8.CrossrefGoogle Scholar

  • 47.

    Debruyne F, Barkin J, van Erps P, Reis M, Tammela TL, Roehrborn C. ARIA3001, ARIA3002 and ARIB3003 study investigators. efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol. 2004;46:488–94.PubMedCrossrefGoogle Scholar

  • 48.

    Na Y, Ye Z, Zhang S. Chinese dutasteride phase III trial (ARIA108898) study group. efficacy and safety of dutasteride in chinese adults with symptomatic benign prostatic hyperplasia: a randomized, double-blind, parallel-group, placebo-controlled study with an open-label extension. Clin Drug Investig. 2012;32:29–39.Google Scholar

  • 49.

    Glina S, Roehrborn CG, Esen A, Plekhanov A, Sorsaburu S, Henneges C, et al. Sexual function in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: results of a 6-month, randomized, double-blind, placebo-controlled study of tadalafil coadministered with finasteride. J Sex Med. 2015;12:129–38.CrossrefPubMedGoogle Scholar

  • 50.

    Tsunemi Y, Irisawa R, Yoshiie H, Brotherton B, Ito H, Tsuboi R, et al. ARI114264 study group. long-term safety and efficacy of dutasteride in the treatment of male patients with androgenetic alopecia. J Dermatol. 2016;43:1051–8.CrossrefGoogle Scholar

  • 51.

    Chi BH, Kim SC. Changes in sexual function in benign prostatic hyperplasia patients taking dutasteride: 1-year follow-up results. Korean J Urol. 2011;52:632–6.PubMedCrossrefGoogle Scholar

  • 52.

    Chiriacò G, Cauci S, Mazzon G, Trombetta C. An observational retrospective evaluation of 79 young men with long-term adverse effects after use of finasteride against androgenetic alopecia. Andrology. 2016;4:245–50.CrossrefPubMedGoogle Scholar

  • 53.

    Cauci S, Chiriacò G, Cecchin E, Toffoli G, Xodo S, Stinco G, et al. Androgen receptor (AR) gene (CAG)n and (GGN)n length polymorphisms and symptoms in young males with long-lasting adverse effects after finasteride use against androgenic alopecia. Sex Med. 2017;5:e61–71.CrossrefGoogle Scholar

  • 54.

    Melcangi RC, Caruso D, Abbiati F, Giatti S, Calabrese D, Piazza F, et al. Neuroactive steroid levels are modified in cerebrospinal fluid and plasma of post-finasteride patients showing persistent sexual side effects and anxious/depressive symptomatology. J Sex Med. 2013;10:2598–603.PubMedCrossrefGoogle Scholar

  • 55.

    Caruso D, Abbiati F, Giatti S, Romano S, Fusco L, Cavaletti G, et al. Patients treated for male pattern hair with finasteride show, after discontinuation of the drug, altered levels of neuroactive steroids in cerebrospinal fluid and plasma. J Steroid Biochem Mol Biol. 2015;146:74–9.PubMedCrossrefGoogle Scholar

  • 56.

    Ali AK, Heran BS, Etminan M. Persistent sexual dysfunction and suicidal ideation in young men treated with low-dose finasteride: a pharmacovigilance study. Pharmacotherapy. 2015;35:687–95.CrossrefPubMedGoogle Scholar

  • 57.

    Choi GS, Kim JH, Oh SY, Park JM, Hong JS, Lee YS, et al. Safety and tolerability of the dual 5-alpha reductase inhibitor dutasteride in the treatment of androgenetic alopecia. Ann Dermatol. 2016;28:444–50.CrossrefPubMedGoogle Scholar

  • 58.

    Guo M, Heran B, Flannigan R, Kezouh A, Etminan M. Persistent sexual dysfunction with finasteride 1 mg taken for hair loss. Pharmacotherapy. 2016;36:1180–4.PubMedCrossrefGoogle Scholar

  • 59.

    Basaria S, Jasuja R, Huang G, Wharton W, Pan H, Pencina K, et al. Characteristics of men who report persistent sexual symptoms after finasteride use for hair loss. J Clin Endocrinol Metab. 2016;101:4669–80.CrossrefPubMedGoogle Scholar

  • 60.

    Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349:215–24.CrossrefPubMedGoogle Scholar

  • 61.

    McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride long-term efficacy and safety study group. N Engl J Med. 1998;338:557–63.CrossrefGoogle Scholar

  • 62.

    Norman RW, Coakes KE, Wright AS, Rittmaster RS. Androgen metabolism in men receiving finasteride before prostatectomy. J Urol. 1993;150:1736–9.PubMedCrossrefGoogle Scholar

  • 63.

    Matzkin H, Chen J, Weisman Y, Goldray D, Pappas F, Jaccard N, et al. Prolonged treatment with finasteride (a 5 alpha-reductase inhibitor) does not affect bone density and metabolism. Clin Endocrinol (Oxf). 1992;137:432–6.Google Scholar

  • 64.

    McConnell JD, Wilson JD, George FW, Geller J, Pappas F, Stoner E. Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab. 1992;74:505–8.PubMedGoogle Scholar

  • 65.

    Dallob AL, Sadick NS, Unger W, Lipert S, Geissler LA, Gregoire SL, et al. The effect of finasteride, a 5 alpha-reductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations in patients with male pattern baldness. J Clin Endocrinol Metab. 1994;79:703–6.PubMedGoogle Scholar

  • 66.

    Van Hecken A, Depré M, Schwartz JI, Tjandramaga TB, Winchell GA, De Lepeleire I, et al. Plasma concentrations and effect on testosterone metabolism after single doses of MK-0434, a steroid 5 alpha-reductase inhibitors, in healthy subjects. Eur J Clin Pharmacol. 1994;46:123–6.CrossrefPubMedGoogle Scholar

  • 67.

    Schwartz JI, Tanaka WK, Wang DZ, Ebel DL, Geissler LA, Dallob A, et al. MK-386, an inhibitor of 5alpha-reductase type 1, reduces dihydrotestosterone concentrations in serum and sebum without affecting dihydrotestosterone concentrations in semen. J Clin Endocrinol Metab. 1997;82:1373–7.PubMedGoogle Scholar

  • 68.

    Bayram F, Müderris II, Sahin Y, Keleştimur F. Finasteride treatment for one year in 35 hirsute patients. Exp Clin Endocrinol Diabetes. 1999;107:195–7.PubMedGoogle Scholar

  • 69.

    Denti L, Pasolini G, Cortellini P, Sanfelici L, Benedetti R, Cecchetti A, et al. Changes in HDL-cholesterol and lipoprotein Lp(a) after 6-month treatment with finasteride in males affected by benign prostatic hyperplasia (BPH). Atherosclerosis. 2000;152:159–66.CrossrefPubMedGoogle Scholar

  • 70.

    Drake L, Hordinsky M, Fiedler V, Swinehart J, Unger WP, Cotterill PC, et al. The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia. J Am Acad Dermatol. 1999;41:550–4.PubMedGoogle Scholar

  • 71.

    Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. J Clin Endocrinol Metab. 2004;89:2179–84.PubMedCrossrefGoogle Scholar

  • 72.

    Ryu HK, Kim KM, Yoo EA, Sim WY, Chung BC. Evaluation of androgens in the scalp hair and plasma of patients with male-pattern baldness before and after finasteride administration. Br J Dermatol. 2006;154:730–4.PubMedCrossrefGoogle Scholar

  • 73.

    Caserini M, Radicioni M, Leuratti C, Annoni O, Palmieri R. A novel finasteride 0.25% topical solution for androgenetic alopecia: pharmacokinetics and effects on plasma androgen levels in healthy male volunteers. Int J Clin Pharmacol Ther. 2014;52:842–9.CrossrefPubMedGoogle Scholar

  • 74.

    Vermeulen A, Giagulli VA, De Schepper P, Buntinx A. Hormonal effects of a 5 alpha-reductase inhibitor (finasteride) on hormonal levels in normal men and in patients with benign prostatic hyperplasia. Eur Urol. 1991;20(Suppl 1):82–86.PubMedCrossrefGoogle Scholar

  • 75.

    Fruzzetti F, de Lorenzo D, Parrini D, Ricci C. Effects of finasteride, a 5 alpha-reductase inhibitor, on circulating androgens and gonadotropin secretion in hirsute women. J Clin Endocrinol Metab. 1994;79:831–5.PubMedGoogle Scholar

  • 76.

    Rittmaster RS, Lemay A, Zwicker H, Capizzi TP, Winch S, Moore E, et al. Effect of finasteride, a 5 alpha-reductase inhibitor, on serum gonadotropins in normal men. J Clin Endocrinol Metab. 1992;75:484–8.PubMedGoogle Scholar

  • 77.

    Rittmasster RS, Stoner R, Thompson DL, Nance D, Lasseter II KC. Effect of MK-906, a specific 5a-reductase inhibitor, on serum androgens and androgen conjugates in normal men. J Androl. 1989;10:259–62.CrossrefGoogle Scholar

  • 78.

    Geller J. Effect of finasteride, a 5 alpha-reductase inhibitor on prostate tissue androgens and prostate-specific antigen. J Clin Endocrinol Metab. 1990;71:1552–5.PubMedCrossrefGoogle Scholar

  • 79.

    Zhao XF, Yang Y, Wang W, Qiu Z, Zhang P, Wang B. Effects of competitive and noncompetitive 5α-reductase inhibitors on serum and intra-prostatic androgens in beagle dogs. Chin Med J (Engl). 2013;126:711–5.PubMedGoogle Scholar

  • 80.

    Olsen EA, Hordinsky M, Whiting D, Stough D, Hobbs S, Ellis ML, et al. Dutasteride alopecia research team. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol. 2006;55:1014–23.CrossrefGoogle Scholar

  • 81.

    Roehrborn CG, Lee M, Meehan A, Waldstreicher J. PLESS study group. effects of finasteride on serum testosterone and body mass index in men with benign prostatic hyperplasia. Urology. 2003;62:894–9.CrossrefGoogle Scholar

  • 82.

    Hong SK, Min GE, Ha SB, Doo SH, Kang MY, Park HJ, et al. Effect of the dual 5alpha-reductase inhibitor, dutasteride, on serum testosterone and body mass index in men with benign prostatic hyperplasia. BJU Int. 2010;105:970–4.PubMedCrossrefGoogle Scholar

  • 83.

    Matsumoto AM, Tenover L, McClung M, Mobley D, Geller J, Sullivan M, et al. Pless study group. The long-term effect of specific type II 5alpha-reductase inhibition with finasteride on bone mineral density in men: results of a 4-year placebo controlled trial. J Urol. 2002;167:2105–8.CrossrefGoogle Scholar

  • 84.

    Stanczyk FZ, Azen CG, Pike MC. Effect of finasteride on serum levels of androstenedione, testosterone and their 5α-reduced metabolites in men at risk for prostate cancer. J Steroid Biochem Mol Biol. 2013;138:10–6.CrossrefPubMedGoogle Scholar

  • 85.

    Uygur MC, Arik AI, Altuğ U, Erol D. Effects of the 5 alpha-reductase inhibitor finasteride on serum levels of gonadal, adrenal, and hypophyseal hormones and its clinical significance: a prospective clinical study. Steroids. 1998;63:208–13.CrossrefPubMedGoogle Scholar

  • 86.

    Schwartz JI, Van Hecken A, De Schepper PJ, De Lepeleire I, Lasseter KC, Shamblen EC, et al. Effect of MK-386, a novel inhibitor of type 1 5 alpha-reductase, alone and in combination with finasteride, on serum dihydrotestosterone concentrations in men. J Clin Endocrinol Metab. 1996;81:2942–7.PubMedGoogle Scholar

  • 87.

    Kacker R, Harisaran V, Given L, Miner M, Rittmaster R, Morgentaler A. Dutasteride in men receiving testosterone therapy: a randomised, double-blind study. Andrologia. 2015;47:148–52.CrossrefPubMedGoogle Scholar

  • 88.

    Yamana K, Labrie F, Luu-The V. Human type 3 5α-reductase is expressed in peripheral tissues at higher levels than types 1 and 2 and its activity is potently inhibited by finasteride and dutasteride. Horm Mol Biol Clin Investig. 2010;2:293–9.PubMedGoogle Scholar

  • 89.

    Kahrizi Kimia, et al. Next generation sequencing in a family with autosomal recessive Kahrizi syndrome (OMIM 612713) reveals a homozygous frameshift mutation in SRD5A3. European Journal of Human Genetics. 2010;19:115–117.Google Scholar

  • 90.

    Cantagrel V, Lefeber DJ, Ng BG, Guan Z, Silhavy JL, Bielas SL. SRD5A3 is required for converting polyprenol to dolichol and is mutated in a congenital glycosylation disorder. Cell. 2010;142:203–17.CrossrefGoogle Scholar

About the article

Received: 2017-03-27

Accepted: 2017-05-03

Published Online: 2017-06-21

Author Statement

Research funding: Authors state no funding involved.

Conflict of interest: Authors state no conflict of interest.

Informed consent: All patients gave their informed consent to be included in this study, and in accordance to the rules of the German Medical Association for evaluation of patient data from patients receiving standard therapy.

Ethical approval: The research related to human use complied with all the relevant national regulations and institutional policies and was performed in accordance to the tenets of the Helsinki Declaration and has been approved by the author’s institutional review board or equivalent committee.

Citation Information: Hormone Molecular Biology and Clinical Investigation, Volume 30, Issue 3, 20170015, ISSN (Online) 1868-1891, ISSN (Print) 1868-1883, DOI: https://doi.org/10.1515/hmbci-2017-0015.

Export Citation

©2017 Walter de Gruyter GmbH, Berlin/Boston.Get Permission

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

M. Zahid Kocak, Gulali Aktas, Tuba T. Duman, Burcin M. Atak, Satilmis Bilgin, Ozge Kurtkulagi, and Haluk Savli
The Aging Male, 2019, Page 1
Li Wei, Edward Chia-Cheng Lai, Yea-Huei Kao-Yang, Brian R Walker, Thomas M MacDonald, and Ruth Andrew
BMJ, 2019, Page l1204
Hiroki Maita, Tadashi Kobayashi, Hiroshi Hiroshi Osawa, Takahiro Hirano, and Hiroyuki Kato
International Journal of Family & Community Medicine, 2017, Volume 1, Number 3
In-suk Bae and Seung-hyun Jung
The Journal of Internal Korean Medicine, 2018, Volume 39, Number 4, Page 592
Cosimo De Nunzio, Riccardo Lombardo, Giorgia Tema, and Andrea Tubaro
Current Urology Reports, 2018, Volume 19, Number 8
George Asare, Yvonne Anang, Daniel Afriyie, Brodrick Amoah, Bernice Asiedu, Derek Doku, Hannah Ocansey, Nana Odei Danso, Prince Tekpor, and Sarah Osam
Medicines, 2017, Volume 4, Number 4, Page 84

Comments (0)

Please log in or register to comment.
Log in